Filtered By:
Cancer: Lung Cancer
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 341 results found since Jan 2013.
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection
CONCLUSIONS: In a standard clinical practice setting, the most prevalent respiratory diseases (asthma, COPD and lung cancer) are related to a higher risk of HZ and PHN. These data are fundamental to assess the potential impact of vaccination in this population.PMID:37734964 | DOI:10.1016/j.arbres.2023.08.010
Source: Archivos de Bronconeumologia - September 21, 2023 Category: Respiratory Medicine Authors: Diego Morena Sara Lumbreras Jos é Miguel Rodríguez Carolina Campos Mar ía Castillo Mar ía Benavent Jos é Luis Izquierdo Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Developments in targeted therapy & amp; immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review
CONCLUSIONS: This review encompasses the latest updates in targeted therapy and immunotherapy in lung cancer management and discusses the future direction in the field.PMID:37675321 | PMC:PMC10477626 | DOI:10.21037/atm-22-4444
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Molly S C Li Kevin K S Mok Tony S K Mok Source Type: research
Patient Report on the Impact of Coronavirus Disease 2019 and Living With Lung Cancer
CONCLUSIONS: An integrative patient-reported view on the impact of COVID-19 is important for adequate preparation to ensure undisrupted treatment and allocation of resources.PMID:37663676 | PMC:PMC10472288 | DOI:10.1016/j.jtocrr.2023.100549
Source: Clinical Lung Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Tendai M Chihuri Upal Basu Roy Amy Moore Anne-Marie Baird Tracey L Grant Bellinda L King-Kallimanis Source Type: research
Breast cancer vaccines; A comprehensive and updated review
Pathol Res Pract. 2023 Aug 4;249:154735. doi: 10.1016/j.prp.2023.154735. Online ahead of print.ABSTRACTAccording to the International Agency for Research on Cancer, breast cancer is more common than lung cancer globally. By 2040, mortality from breast cancer will rise by 50% and 40%, respectively. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy, breast cancer metastases and recurrences remain challenging to treat. Cancer vaccines are an effective treatment option because they stimulate a long-lasting immune response that will eliminate tumor cells. In studies on the breast cancer vaccine, no ...
Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Sulieman Ibraheem Shelash Al-Hawary Ebraheem Abdu Musad Saleh Nodirjon Akhmetovich Mamajanov Nataliya S Gilmanova Hashem O Alsaab Adel Alghamdi Shakeel Ahmed Ansari Ahmed Hussien Radie Alawady Ali Hashiem Alsaalamy Ahmed Jaber Ibrahim Source Type: research
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
Elife. 2023 Aug 7;12:e85263. doi: 10.7554/eLife.85263. Online ahead of print.ABSTRACTCancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can induce control of cancer growth, with a fraction of patients experiencing durable responses. However, the majority of patients currently do not respond to CBT and the molecular determinants of resistance have not been fully elucidated. Mounting clinical evidence suggests that the clonal status of neoantigens (NeoAg) impacts the anti-tumor T cell response. High intratumor heterogeneity (ITH), where the majority of NeoAgs are expressed subclonally, is correlat...
Source: Cancer Control - August 7, 2023 Category: Cancer & Oncology Authors: Kim Bich Nguyen Malte Roerden Christopher J Copeland Coralie M Backlund Nory G Klop-Packel Tanaka Remba Byungji Kim Nishant K Singh Michael E Birnbaum Darrell J Irvine Stefani Spranger Source Type: research
Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine
Mol Ther Methods Clin Dev. 2023 Jun 27;30:194-207. doi: 10.1016/j.omtm.2023.06.009. eCollection 2023 Sep 14.ABSTRACTBecause of continual generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is critical to design the next generation of vaccines to combat the threat posed by SARS-CoV-2 variants. We developed human adenovirus (HAd) vector-based vaccines (HAd-Spike/C5 and HAd-Spike) that express the whole Spike (S) protein of SARS-CoV-2 with or without autophagy-inducing peptide C5 (AIP-C5), respectively. Mice or golden Syrian hamsters immunized intranasally (i.n.) with HAd-Spike/C5 in...
Source: Clinical Lung Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Ekramy E Sayedahmed Marcelo Valdemir Ara újo Taiana Tain á Silva-Pereira Shubhada K Chothe Ahmed Elkashif Marwa Alhashimi Wen-Chien Wang Andrea P Santos Meera Surendran Nair Abhinay Gontu Ruth Nissly Ant ônio Francisco de Souza Filho Mariana Silva Tava Source Type: research
